


## Feniralstat

Cat. No.:	HY-145568		
CAS No.:	2166320-76-7		
Molecular Formula:	C <sub>26</sub> H <sub>25</sub> F <sub>2</sub> N <sub>5</sub> O <sub>4</sub>		
Molecular Weight:	509.5		
Target:	Ser/Thr Protease		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (196.27 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.9627 mL	9.8135 mL	19.6271 mL
5 mM	0.3925 mL	1.9627 mL	3.9254 mL
10 mM	0.1963 mL	0.9814 mL	1.9627 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 1.25 mg/mL (2.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1.25 mg/mL (2.45 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 1.25 mg/mL (2.45 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC<sub>50</sub> of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLK1, Human FX1a, Human Factor XIIa (all IC<sub>50</sub>>40 μM).

### REFERENCES

- [1]. Rebecca Louise DAVIE, et al. Pyrazole derivatives as plasma kallikrein inhibitors. WO2017207983A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA